162 related articles for article (PubMed ID: 8646796)
1. Antitumour evaluation of dolastatins 10 and 15 and their measurement in plasma by radioimmunoassay.
Aherne GW; Hardcastle A; Valenti M; Bryant A; Rogers P; Pettit GR; Srirangam JK; Kelland LR
Cancer Chemother Pharmacol; 1996; 38(3):225-32. PubMed ID: 8646796
[TBL] [Abstract][Full Text] [Related]
2. cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice.
Raynaud FI; Boxall FE; Goddard PM; Valenti M; Jones M; Murrer BA; Abrams M; Kelland LR
Clin Cancer Res; 1997 Nov; 3(11):2063-74. PubMed ID: 9815598
[TBL] [Abstract][Full Text] [Related]
3. Growth inhibition of human lymphoma cell lines by the marine products, dolastatins 10 and 15.
Beckwith M; Urba WJ; Longo DL
J Natl Cancer Inst; 1993 Mar; 85(6):483-8. PubMed ID: 8445676
[TBL] [Abstract][Full Text] [Related]
4. Successful treatment of human chronic lymphocytic leukemia xenografts with combination biological agents auristatin PE and bryostatin 1.
Mohammad RM; Varterasian ML; Almatchy VP; Hannoudi GN; Pettit GR; Al-Katib A
Clin Cancer Res; 1998 May; 4(5):1337-43. PubMed ID: 9607595
[TBL] [Abstract][Full Text] [Related]
5. Activity of dolastatin 10 against small-cell lung cancer in vitro and in vivo: induction of apoptosis and bcl-2 modification.
Kalemkerian GP; Ou X; Adil MR; Rosati R; Khoulani MM; Madan SK; Pettit GR
Cancer Chemother Pharmacol; 1999; 43(6):507-15. PubMed ID: 10321512
[TBL] [Abstract][Full Text] [Related]
6. Sustained intracellular retention of dolastatin 10 causes its potent antimitotic activity.
Verdier-Pinard P; Kepler JA; Pettit GR; Hamel E
Mol Pharmacol; 2000 Jan; 57(1):180-7. PubMed ID: 10617693
[TBL] [Abstract][Full Text] [Related]
7. Dolastatin 15 induces apoptosis and BCL-2 phosphorylation in small cell lung cancer cell lines.
Ali MA; Rosati R; Pettit GR; Kalemkerian GP
Anticancer Res; 1998; 18(2A):1021-6. PubMed ID: 9615758
[TBL] [Abstract][Full Text] [Related]
8. Preclinical pharmacology of the natural marine product dolastatin 10 (NSC 376128).
Newman RA; Fuentes A; Covey JM; Benvenuto JA
Drug Metab Dispos; 1994; 22(3):428-32. PubMed ID: 8070319
[TBL] [Abstract][Full Text] [Related]
9. Bradykinin antagonist dimer, CU201, inhibits the growth of human lung cancer cell lines in vitro and in vivo and produces synergistic growth inhibition in combination with other antitumor agents.
Chan DC; Gera L; Stewart JM; Helfrich B; Zhao TL; Feng WY; Chan KK; Covey JM; Bunn PA
Clin Cancer Res; 2002 May; 8(5):1280-7. PubMed ID: 12006549
[TBL] [Abstract][Full Text] [Related]
10. Novel phosphonium salts display in vitro and in vivo cytotoxic activity against human ovarian cancer cell lines.
Manetta A; Gamboa G; Nasseri A; Podnos YD; Emma D; Dorion G; Rawlings L; Carpenter PM; Bustamante A; Patel J; Rideout D
Gynecol Oncol; 1996 Feb; 60(2):203-12. PubMed ID: 8631539
[TBL] [Abstract][Full Text] [Related]
11. Antineoplastic dolastatins: potent inhibitors of hematopoietic progenitor cells.
Jacobsen SE; Ruscetti FW; Longo DL; Keller JR
J Natl Cancer Inst; 1991 Nov; 83(22):1672-7. PubMed ID: 1749020
[TBL] [Abstract][Full Text] [Related]
12. Antineoplastic agents 365. Dolastatin 10 SAR probes.
Pettit GR; Srirangam JK; Barkoczy J; Williams MD; Boyd MR; Hamel E; Pettit RK; Hogan F; Bai R; Chapuis JC; McAllister SC; Schmidt JM
Anticancer Drug Des; 1998 Jun; 13(4):243-77. PubMed ID: 9627667
[TBL] [Abstract][Full Text] [Related]
13. Dolastatin 10, a powerful cytostatic peptide derived from a marine animal. Inhibition of tubulin polymerization mediated through the vinca alkaloid binding domain.
Bai R; Pettit GR; Hamel E
Biochem Pharmacol; 1990 Jun; 39(12):1941-9. PubMed ID: 2353935
[TBL] [Abstract][Full Text] [Related]
14. Correlation of pharmacokinetics with the antitumor activity of Cetuximab in nude mice bearing the GEO human colon carcinoma xenograft.
Luo FR; Yang Z; Dong H; Camuso A; McGlinchey K; Fager K; Flefleh C; Kan D; Inigo I; Castaneda S; Rose WC; Kramer RA; Wild R; Lee FY
Cancer Chemother Pharmacol; 2005 Nov; 56(5):455-64. PubMed ID: 15947929
[TBL] [Abstract][Full Text] [Related]
15. Treatment of human prostate cancer cells with dolastatin 10, a peptide isolated from a marine shell-less mollusc.
Turner T; Jackson WH; Pettit GR; Wells A; Kraft AS
Prostate; 1998 Feb; 34(3):175-81. PubMed ID: 9492845
[TBL] [Abstract][Full Text] [Related]
16. Dolastatin 15, a potent antimitotic depsipeptide derived from Dolabella auricularia. Interaction with tubulin and effects of cellular microtubules.
Bai R; Friedman SJ; Pettit GR; Hamel E
Biochem Pharmacol; 1992 Jun; 43(12):2637-45. PubMed ID: 1632820
[TBL] [Abstract][Full Text] [Related]
17. Differential effects of active isomers, segments, and analogs of dolastatin 10 on ligand interactions with tubulin. Correlation with cytotoxicity.
Bai R; Roach MC; Jayaram SK; Barkoczy J; Pettit GR; Ludueña RF; Hamel E
Biochem Pharmacol; 1993 Apr; 45(7):1503-15. PubMed ID: 8471072
[TBL] [Abstract][Full Text] [Related]
18. Antitumor activity of TZT-1027, a novel dolastatin 10 derivative.
Kobayashi M; Natsume T; Tamaoki S; Watanabe J; Asano H; Mikami T; Miyasaka K; Miyazaki K; Gondo M; Sakakibara K; Tsukagoshi S
Jpn J Cancer Res; 1997 Mar; 88(3):316-27. PubMed ID: 9140117
[TBL] [Abstract][Full Text] [Related]
19. Dolastatin 10 and dolastatin 15: effects of two natural peptides on growth and differentiation of leukemia cells.
Steube KG; Grunicke D; Pietsch T; Gignac SM; Pettit GR; Drexler HG
Leukemia; 1992 Oct; 6(10):1048-53. PubMed ID: 1405759
[TBL] [Abstract][Full Text] [Related]
20. Effects of the antimitotic natural product dolastatin 10, and related peptides, on the human malarial parasite Plasmodium falciparum.
Fennell BJ; Carolan S; Pettit GR; Bell A
J Antimicrob Chemother; 2003 Apr; 51(4):833-41. PubMed ID: 12654761
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
